スタッフ紹介
業績集
田中 良哉
受賞歴
平成１５年 日本骨代謝学会学術賞
平成２０年 日本リウマチ学会賞
平成２１年 欧州リウマチ学会賞
令和 ５年 欧州リウマチ学会栄誉賞
令和 ５年 日本骨代謝学会学会賞 など
論文 （令和７年１月現在）
著書 邦文４１９編 欧文 １４編
総説 邦文９５３編 欧文１５２編
原著 邦文 ５１編 欧文７４９編
症例報告 邦文１７６編 欧文１２２編
合計 邦文１，５９９編 欧文１，０３７編
総計2,636編
Expert Scape 関節リウマチ領域 世界第1位
h-index 115
インパクト・ファクター 6221.1
宮川 一平
受賞歴
令和3年 第2回日本ベーチェット病学会奨励賞（稲葉・大野賞）
平成31年 第63回日本リウマチ学会 国際ワークショップ賞
平成30年 第36回産業医科大学学会学長賞
平成30年 EULAR Abstract Awards 2018 in Clinical Science
平成30年 第62回日本リウマチ学会 国際ワークショップ賞
平成29年 19th Asia Pacific League of Associations for Rheumatology Congress
APLAR2017 CELLTRION Best Abstract Award
平成29年 第38回日本炎症・再生医学会 優秀演題賞
平成29年 第61回日本リウマチ学会 国際ワークショップ賞
平成28年 第2回日本骨免疫学会 優秀演題賞
平成28年 第60回日本リウマチ学会 国際ワークショップ賞
平成27年 第59回日本リウマチ学会 国際ワークショップ賞
平成26年 第36回日本炎症・再生医学会 優秀演題賞
平成23年 第55回日本リウマチ学会 国際ワークショップ賞
論文
（文責：久保智史 更新日2023/4/20）
このページの先頭へ
1. Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, Hanami
K, Fukuyo S, Miyagawa I, Kubo S, Tanaka Y. Phenotypic changes of lymphocytes
in patients with systemic lupus erythematosus who are in longterm remission
after B cell depletion therapy with rituximab. J Rheumatol; 2011; 4:633-41
2. Tanaka Y, Yamanaka H, Saito K, Iwata S, Miyagawa I, Seto Y, Momohara
S, Nagasawa H, Kameda H, Kaneko Y, Izumi K, Amano K, Takeuchi T. Structural
damage disturb functional improvement in patients with rheumatoid arthritis
treated with etanercept. Mod Rheumatol. 2012; 22:186-94.
3. Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Kubo S, Miyagawa I, Sonomoto
K, Saito K, Tanaka Y. Dermal mast cell density in fingers reflects severity
of skin sclerosis in systemic sclerosis. Mod Rheumatol. 2013; 23:1151-7
4. Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatol. 2014; 24:405-9
5. Zhang X, Yamaoka K, Sonomoto K, Kaneko H, Satake M, Yamamoto Y, Kondo
M, Zhao J, Miyagawa I, Yamagata K, Fukuyo S, Okada Y, Tanaka Y. Local delivery
of mesenchymal stem cells with poly-lactic-co-glycolic acid nano-fiber
scaffold suppress arthritis in rats. PLoS One. 2014; 9: e114621.
6. Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, Hanami
K, Saito K, Tanaka Y. Comparison of the efficacies of abatacept and tocilizumab
in patients with rheumatoid arthritis by propensity score matching. Ann
Rheum Dis. 2016:7;1321-7
7. Yoshinari H, Saito K, Nakano K, Fukuyo S, Miyagawa I, Tanaka Y. A case of rheumatoid arthritis treated with infliximab who developed disseminated Penicillium marneffei infection after visit to Thailand. Modern Rheumatology Case Reports 2017
8. Ishikawa Y, Miyagawa I, Nakano K, Satoh Y, Todoroki Y, Kubo S, Nawata
A, Nakayamada S, Saito K, Tanaka Y. The occurrence of hypertrophic pachymeningitis
with infiltration of IgG4-positive plasma cells and with different aetiology:
report of three cases. Modern Rheumatology Case Reports 2017
9. Miyagawa I, Nakayamada S, Nakano K, Yamagata K, Sakata K, Yamaoka K,
Tanaka Y. Induction of Regulatory T Cells and Its Regulation with Insulin-like
Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal
Stem Cells. J Immunol. 2017.199; 1616-1625
10. Nakayamada S, Kubo S, Yoshikawa M, Miyazaki Y, Yunoue N, Iwata S, Miyagawa
I, Hirata S, Nakano K, Saito K, Tanaka Y. Differential effects of biological
DMARDs on peripheral immune cell phenotypes in patients with rheumatoid
arthritis. Rheumatology (Oxford) 2018;1;57:164-174. DOI: 10.1093/rheumatology/kex012.
11. Kubo S, Nakayamada S, Yoshikawa M, Miyazaki Y, Sakata K, Nakano K, Hanami K, Iwata S, Miyagawa I, Saito K, Tanaka Y. Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. Arthritis Rheumatol. 2017.69; 2029-2037
12. Ohkubo N, Nakano K, Miyagawa I, Iwata S, Fukuyo S, Kubo S, Tamaki Y,
Nakayamada S, Tanaka Y. Successful treatment with etanercept in a case
of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant
pemphigus erythematosus. Modern Rheumatology Case Reports 2018.
13. Nagayasu A, Kubo S, Nakano K, Nakayamada S, Iwata S, Miyagawa I, Fukuyo
S, Saito K, Tanaka Y. IgG4-related Pleuritis with Elevated Adenosine Deaminase
in Pleural Effusion: A Case Report. ntern Med. 2018;57:2251-2257. doi:
10.2169/internalmedicine.0387-17.
14. Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus 2018;27:802-811. Doi: 0.1177/0961203317749047.
15. Satoh Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa
I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y. A case of refractory lupus
nephritis complicated by psoriasis vulgaris that was controlled with secukinumab.
Lupus 2018;27:1202-1206. Doi: 10.1177/0961203318762598.
16. Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, Yoshikawa
M, Yoshinari H, Tanaka Y. Precision medicine using different biological
DMARDs based on characteristic phenotypes of peripheral T helper cells
in psoriatic arthritis. Rheumatology (Oxford) 2019:1;58:336-344. Doi: 10.1093/rheumatology/key069.
17. Kubo S, Todoroki Y, Nakayamada S, Nakano K, Satoh M, Nawata A, Satoh Y, Miyagawa I, Saito K, V Smith, M Cutolo, Tanaka Y. Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatology (Oxford) 2019.1;58:120-130. DOI: 10.1093/rheumatology/key257.
18. Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo
S, Inoue Y, Ueno M, Tanaka Y. The effectiveness and safety of hydroxychloroquine
therapy with or without corticosteroid in patients with systemic lupus
erythematosus. Int J Rheum.Dis. 2019;22:434-442. doi: 10.1111/1756-185X.13387
(ア)
19. Ueno M, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa
I, Tanaka Y. An Autopsy Case with Cerebral Hemorrhaging Due to Disseminated
Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic
Lupus Erythematosus and Systemic Sclerosis. Intern Med. 2019;58:1023-1027.
doi: 10.2169/internalmedicine.1226-18.
20. Miyagawa I, Nakayamada S, Masahiro Kondo, Tanaka Y. Regulatory mechanism of the induction of regulatory T cells through growth factors released by human mesenchymal stem cells. Critical Reviews in Immunology. 2018. DOI:10.1615/CritRevImmunol.2018027821
21. Miyazaki Y, Nakayamada S, Kubo S, Nakano K, Iwata S, Miyagawa I, Ma
X, Trimova G, Sakata K, Tanaka Y. Th22 Cells Promote Osteoclast Differentiation
via Production of IL-22 in Rheumatoid Arthritis. Front Immunol. 2018:10;9:2901.
doi:10.3389/fimmu.2018.02901.
22. Miyagawa I, Nakayamada S, Tanaka Y. Optimal Biologic Selection for
Treatment of Psoriatic Arthritis: The approach to precision medicine. Current
Rheumatol Rep. 2019;21:21. doi: 10.1007/s11926-019-0817-x.
23. Satoh Y, Nakano K, Miyazaki Y, Nakayamada S, Fukuyo S, Kubo S, Miyagawa I, Yoshinari H, Saito K, Satoh M, Tanaka Y. The two case of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects. Modern Rheumatology Case Reports. 2019. DOI: 10.1080/24725625.2018.1549928
24. Tanaka Y, Kubo S, Miyagawa I, Iwata S, Nakayamada S. Lymphocyte phenotype
and its application to precision medicine in systemic autoimmune diseases.
Semin Arthritis Rheum. 2019;48:1146-1150. DOI: 10.1016/j.semarthrit.2019.04.007.
25. Miyagawa I, Nakano K, Iwata S, Nakayamada S, Saito K, Hanami K, Fukuyo
S, Kubo S, Kawabe A, Miyazaki Y, Tanaka Y. Comparative study of corticosteroid
monotherapy, and TNF inhibitors with or without corticosteroid in patients
with refractory entero-Behcet’s disease. Arthritis Res Ther. 2019:21:151.
doi.org/10.1186/s13075-019-1933-8
26. Miyagawa I, Nakano K, Nakayamada S, Mori H, Okada Y, Saito K, Tanaka Y. A case of systemic lupus erythematosus in which Cushing’s syndrome caused by adrenal adenoma accidentally occurred during long-term maintenance therapy with corticosteroids. Modern Rheumatology Case Reports. 2019. DOI:10.1080/24725625.2019.1651488
27. Yamauchi Y, Nakano K, Miyagawa I, Inaba Y, Nawata A, Sato N, Kumei
S, Kawanami T, Yatera K, Tanaka Y. An Autopsy Case of a Patient with Systemic
Sclerosis Who Developed Marked Pulmonary Hypertension Because of Pulmonary
Tumor Thrombotic Microangiopathy Caused by Gastric Carcinoma. Modern Rheumatology
Case Reports. 4.55-62. 2019
28. Miyagawa I, Tanaka Y. Is precision medicine possible in rheumatic diseases?
Lessons from selective use of targeted therapies in patients with psoriatic
arthritis. Expert Rev Clin Immunol 16:199-206.2020
29. Tanaka Y, Kuwana M, Fujii T, Kameda H, Muro Y, Fujio K, Itoh Y, Yasuoka H, Fukaya S, Ashihara K, Hirano D, Ohmura K, Tabuchi Y, Hasegawa H, Matsumiya R, Shirai Y, Ogura T, Tsuchida Y, Ogawa-Momohara M, Narazaki H, Inoue Y, Miyagawa I, Nakano K, Hirata S, Mori M. 2019 diagnostic criteria for mixed connective tissue disease: from the Japan Research Committee of the Ministry of Health, Labor, and Welfare for systemic autoimmune diseases. Mod Rheumatol 31:29-33.2021
30. Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo
S, Kawabe A, Miyazaki Y, Inoue Y, Ueno M, Okubo N, Fujita Y, Tanaka Y.
The additive effects of hydroxychloroquine to maintenance therapy with
standard of care in patients with systemic lupus erythematosus. Int J Rheum.Dis.23:196-201.2020
31. Funada M, Nakano K, Miyagawa I, Ueno M, Tanaka Y. Systemic lupus erythematosus
with repeated protein-losing enteropathy resulting from different pathological
conditions: a case report. Modern Rheumatology Case Reports. 4;229-232.2020
32. Nakano K, Saito K, Nawata A, Hanami K, Kubo S, Miyagawa I, Fujino Y, Nakayamada S, Tanaka Y. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. Mod Rheumatol.31:94-100.2021
33. Kanda R, Nakano K, Miyagawa I, Iwata S, Nakayamada S, Tanaka Y. A case
of bone destruction caused by chronic nonbacterial osteomyelitis (CNO)
successfully repaired with a tumor necrosis factor-α (TNF-α) inhibitor,
adalimumab. Modern Rheumatology Case Reports. 4:196-201.2020
34. Ueno M, Nakano K, Miyagawa I, Tanaka Y. Five cases of IgG4-related
diseases with nasal mucosa and sinus involvements. Intern Med. 59:1905-11.
2020
35. Miyagawa I, Tanaka Y. The approach to precision medicine for the treatment of psoriatic arthritis. Immunol Med. 43:98-102.2020 36. Miyazaki Y, Nakayamada S, Kubo S, Ishikawa Y, Yoshikawa M, Sakata K, Iwata S, Miyagawa I, Kazuhisa Nakano K, Tanaka Y. Favorable efficacy of rituximab in ANCA associated vasculitis patients with excessive B cell differentiation. Arthritis Res Ther. 2020:22:141.
37. Ohkubo N, Nakano K, Miyagawa I, Tanaka Y. Mild Encephalitis/Encephalopathy
with Reversible (ア) Splenial Lesions in SLE. Internal Med. 2020 doi: 10.2169/internalmedicine.4612-20.
38. Miyagawa I, Kubo S, Tanaka Y. A wide perspective of targeted therapies
for precision medicine in autoimmune diseases. Expert Rev Precis Med Drug
Dev. 2020
39. Ueno M, Miyagawa I, Nakano K, Iwata S, Hanami K, Fukuyo S, Kubo S, Miyazaki Y, Kawabe A, Yoshinari H, Nakayamada S, Tanaka Y. Effectiveness and Safety of Mepolizumab in Combination with Corticosteroids in patients with Eosinophilic Granulomatosis with Polyangiitis. Arthritis Res Ther 23;1-9.2021
40. Ishikawa S, Miyagawa I, Kusanaga M, Abe T, Shiraishi A, Fujishima S,
Ogura H, Saitoh D, Kushimoto S, Shiino Yasukazu, Hifumi T, Otomo Y, Okamoto
K, Kotani J, Sakamoto Y, Sasaki J, Shiraishi S, Takuma K, Hagiwara A, Yamakawa
K, Takeyama N, Gando S; Mayumi T. Association of frailty on treatment outcomes
among patients with suspected infection treated at emergency departments.
European Journal of Emergency Medicine, 28:285-291.2021
41. Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Iwata S, Hanami K, Fukuyo
S, Miyagawa I, Yamaguchi A, Kawabe A, Saito K, Tanaka Y. Serum TNFα levels
at 24 hours after certolizumab pegol predict effectiveness at week 12 in
patients with rheumatoid arthritis from TSUBAME study. Arthritis Res Ther
23:1-11.2021
42. Ohkubo N, Iwata S, Nakano K, Miyagawa I, Hanami K, Fukuyo S, Miyazaki Y, Kawabe A, Nakayamada S, Tanaka Y. Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis. Mod Rheumatol.2021. DOI: 10.1093/mr/roab113
43. Miyagawa I, Tanaka Y. Dawn of precision medicine in psoriatic arthritis.
Front Med (Lausanne). 682. 2022
44. Ueno M, Miyagawa I, Kawabe A, Kusaka K, Nakayamada S, Tanaka Y. A patient
with eosinophilic granulomatosis with polyangiitis successfully weaned
from corticosteroids through remission induction therapy with mepolizumab.
Modern Rheumatology Case Reports. 2022
45. Todoroki Y, Kubo S, Nakano K, Miyazaki Y, Ueno M, Satoh-Kanda Y, Kanda R, Miyagawa I, Hanami K, Nakatsuka K, Saito K, Nakayamada S, Tanaka Y. Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology (Oxford) 2022
46. Miyagawa I, Nakayamada S, Ueno M, Miyazaki Y, Iwata S, Kubo S, Sonomoto
K, Anan J, Ohkubo N, Inoue Y, Tanaka Y. Impact of serum interleukin 22
as a biomarker for the differential use of molecular targeted drugs in
psoriatic arthritis: A retrospective study. Arthritis Res Ther 2022
47. Ueno M, Miyagawa I, Aritomi T, Kimura K, Iwata S, Hanami K, Fukuyo
S, Kubo S, Miyazaki Y, Nakayamada S, Tanaka Y. Safety and Effectiveness
of Mepolizumab Therapy in Remission Induction Therapy for Eosinophilic
Granulomatosis with Polyangiitis: A Retrospective Study. Arthritis Res
Ther 2022
48. Miyagawa I, Nakayamada S, Ueno M, Miyazaki Y, Ohkubo N, Inoue Y, Kubo S, Tanaka Y. Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One-year follow-up outcomes. Front Med (Lausanne) 2022
49. Kusaka K, Miyagawa I, Kosaka S, Matsunaga S, Nakayamada S, Tanaka Y.
A case of glucocorticoid-resistant adult Still’s disease compicated by
pulmonary hypertension and interstitial lung disease. Modern Rheumatology
Case Reports. 2022
50. Ueno M. Miyagawa I, Miyazaki Y, Hanami K, Fukuyo S, Kubo S, Nakayamada
S, Tanaka Y. Efficacy and Safety of Guselkumab and Adalimumab for Pustulotic
Arthro-Osteitis and their Impact on Peripheral Blood Immunophenotypes.
Arthritis Res Ther 2022
51. Miyagawa I, Tanaka Y. Bimekizumab: a Humanized Monoclonal IgG1 Antibody for the Treatment of Psoriatic Arthritis. touchREVIEWS in RMD 2023 (in press)
52. Kubo S, Miyazaki Y, Todoroki Y, Nagayasu A, Kanda R, Aritomi T, Matsunaga
S, Ueno M, Miyagawa I, Sonomoto K, Hanami K, Nakayamada S, Tanaka Y. Generation-Dependent
Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies
in Patients with Rheumatoid Arthritis: From FIRST Registry. Rheumatol Ther.
2023. doi: 10.1007/s40744-023-00603-8.
53. Miyazaki Y, Funada M, Nakayamada S, Sonomoto K, Tanaka H, Hanami K,
Fukuyo S, Kubo S, Yamaguchi A, Miyagawa I, Todoroki Y, Ueno M, Tanaka Y.
Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus
in real-world clinical practice: LOOPS registry. Rheumatology (Oxford).
2023 （in press）
54. Schalter F, Azizov V, Frech M, Durholz K, Schmid E, Hendel A, Sarfati I, Maeda Y, Sokolova M, Miyagawa I, Focke K, Sarter K, van Baarsen LGM, Krautwald S, Schett G, Zaiss MM. CCL19-Positive Lymph Node Stromal Cells Govern the Onset of Inflammatory Arthritis via Tropomyosin Receptor Kinase. Arthritis Rheumatol. 2024;76:857-868.
55. Funada M, Miyazaki Y, Nakayamada S, Sonomoto K, Kubo S, Miyagawa I,
Tanaka H, Tanaka Y. CT informs detection and treatment options in rheumatoid
arthritis complicated by pulmonary non-tuberculous mycobacterial disease
from the FIRST registry. RMD Open. 2024;10:e004049.
56. Miyazaki Y, Nakayamada S, Tanaka H, Hanami K, Fukuyo S, Kubo S, Miyagawa
I, Yamaguchi A, Todoroki Y, Inoue Y, Ueno M, Tanaka Y. Comparison of anti-IL-6
receptor and JAK inhibitors in patients with rheumatoid arthritis from
the real-world practice FIRST study. Rheumatology (Oxford). 2024:keae334.
doi: 10.1093/rheumatology/keae334.
57. Tsugita N, Miyagawa I, Nakayamada S, Nawata A, Kosaka S, Ueno M, Tanaka Y. Epstein-Barr Virus-Encoded RNA-Positive Lymphocytes in Bone Marrow and Lymph Nodes in an Autopsy Case of TAFRO Syndrome. Mod Rheumatol Case Rep. 2024 :rxae049. doi: 10.1093/mrcr/rxae049.
58. Sakai H, Miyazaki Y, Nakayamada S, Kubo S, Hanami K, Fukuyo S, Yamaguchi
A, Miyagawa I, Ueno M, Tanaka H, Todoroki Y, Ohkubo N, Funada M, Matsunaga
S, Tanaka Y. Efficacy, safety, and optimal intervention of belimumab for
proliferative lupus nephritis patients in real-world settings: LOOPS registry.
Rheumatology (Oxford). 2024:keae495. doi: 10.1093/rheumatology/keae495.
59. Kubo S, Miyazaki Y, Nishino T, Fujita Y, Kono M, Kawashima T, Ishigaki
K, Kusaka K, Tanaka H, Ueno M, Satoh-Kanda Y, Inoue Y, Todoroki Y, Miyagawa
I, Hanami K, Nakayamada S, Tanaka Y. Peripheral blood immunophenotypic
diversity in patients with rheumatoid arthritis and its impact on therapeutic
responsiveness. Ann Rheum Dis. 2024 :ard-2024-226228. doi: 10.1136/ard-2024-226228.
60. Kusaka K, Miyazaki Y, Nakayamada S, Kubo S, Miyagawa I, Satoh-Kanda Y, Todoroki Y, Ueno M, Tanaka Y. The abundance of regulatory T cell subsets is associated with the clinical outcomes of sarcoidosis. Mod Rheumatol. 2024 Nov 14:roae106. doi: 10.1093/mr/roae106. Epub ahead of print. PMID: 39539229.
61. Tsugita N, Miyagawa I, Ueno M, Takahashi M, Kosaka S, Nakayamada S,
Tanaka Y：An autopsy of a patient with polyarteritis nodosa who developed
fatal intestinal perforation accompanied by systemic multiple aneurysms
and arterial thrombosis Modern Rheumatology Case Reports (in press)
62. Kyuto Sonehara, Rei Watanabe, Yutaka Matsumura, Kaori Odomari, Saori
Sakaue, Shinichi Namba, Tomomitsu Hirota, Noriko Arase, Yuumi Nakamura,
Kimiko Nakajima, Takashi Okamoto, Rika Nishikawa, Kenichi Yamamoto, Ken
Suzuki, Toshihiro Kishikawa, Ryuya Edahiro, Yuya Shirai, Tatsuhiko Naito,
Noah Sasa, Yosuke Ishitsuka, Junichi Furuta, Kayo Kunimoto, Ikko Kajihara,
Satoshi Fukushima, Hideaki Miyachi, Hiroyuki Matsue, Masahiro Kamata, Mami
Momose, Ippei Miyagawa, Hiroaki Tanaka, Masanobu Ueno, Toshinori Bito,
Hiroshi Nagai, Tetsuya Ikeda, Tatsuya Horikawa, Atsuko Adachi, Tsukasa
Matsubara, Kyoko Ikumi, Emi Nishida, Biobank Japan Project, Koichi Matsuda,
Nobuhiro Shojima, Ikuma Nakagawa, Yoshihide Asano, Shinichi Sato, Shinichi
Imafuku, Yayoi Tada, Chikako Nishigori, Masatoshi Jinnin, Hironobu Ihn,
Akihiko Asahina, Hidehisa Saeki, Toshimasa Yamauchi, Takashi Kadowaki,
Tatsuyoshi Kawamura, Shinji Shimada, Ichiro Katayama, Koichiro Higasa,
Emiko Noguchi, Shigetoshi Sano, Yoshiya Tanaka, Fumihiko Matsuda, Atsushi
Kumanogoh, Mayumi Tamari, Manabu Fujimoto, Akimichi Morita, Yukinori Okada:
Blood DNA virome associates with autoimmune diseases and COVID-19. Nat
Genet(in press)
63. Miyagawa I, Nakayamada S, Nohara H, Kosaka S, Ueno M, Tanaka Y. A case of Erdheim-Chester disease-a mimicker of IgG4-related disease and large vessel vasculitis. Mod Rheumatol Case Rep. 2024 Dec 17:rxae086.
64. Miyagawa I, Nakayamada S, Saito K, Shimizu S, Hanami K, Ueno M, Tanaka
Y. A case of newly onset rheumatoid arthritis successfully treated with
methotrexate under the anti-retrovirus therapy against HIV infection. Mod
Rheumatol Case Rep.rxaf011,2025
65. Ueno M, Iwata S, Yamagata K, Todoroki Y, Sonomoto K, Nagayasu A, Miyagawa
I, Kubo S, Miyazaki Y, Miyata H, Kanda R, Aritomi T, Nakayamada S, Tanaka
Y. Induction of interleukin 21 receptor expression via enhanced intracellular
metabolism in B cells and its relevance to the disease activity in systemic
lupus erythematosus. RMD Open.10,e004567,2024
66. Kanda R, Miyazaki Y, Nakayamada S, Fukuyo S, Kubo S, Miyagawa I, Yamaguchi A, Satoh-Kanda Y, Ohkubo N, Todoroki Y, Ueno M, Nagayasu A, Kusaka K, Sakai H, Matsunaga S, Nohara H, Tanaka Y. Effective Second-line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-line b/tsDMARDs From the FIRST Registry.Rheumatol Ther.2025 (in press)
67. Todoroki Y, Nakayamada S, Miyagawa I, Kubo S, Yoshioka K, Satoh M,
Tanaka Y. Spontaneous Remission in a Patient with Anti-OJ Autoantibodies-positive
Anti-synthetase Syndrome Following SARS-CoV-2 Infection and mRNA Vaccination:
A Case Report. Intern Med. 2025 Mar 1. doi: 10.2169/internalmedicine.4852-24.
Epub ahead of print. PMID: 40024740.
68. Kubo S, Miyazaki Y, Tanaka H, Fujita Y, Sakai H, Ueno M, Todoroki Y,
Satoh-Kanda Y, Miyagawa I, Nakayamada S, Tanaka Y. Transition of clinical
remission rates with molecular targeted therapies in rheumatoid arthritis
in Japan: insights from FIRST registry. Rheumatology (Oxford). 2025 May
13:keaf246. doi: 10.1093/rheumatology/keaf246. Epub ahead of print. PMID:
40358556.
69. Nagayasu A, Miyazaki Y, Sonomoto K, Kubo S, Miyagawa I, Yamaguchi A, Tanaka H, Todoroki Y, Ueno M, Aritomi T, Fujita Y, Sakai H, Suzuki K, Nakayamada S, Tanaka Y. Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis. Rheumatol Ther. 2025 May 16. doi: 10.1007/s40744-025-00769-3. Epub ahead of print. PMID: 40377857.
70. Miyagawa I, Tanaka Y. Precision medicine using molecular-target drugs
in psoriatic arthritis. Ther Adv Musculoskelet Dis. 2025 Jan 5;17:1759720X241311462.
doi: 10.1177/1759720X241311462. PMID: 39776828; PMCID: PMC11701904.
71. Sonehara K, Watanabe R, Matsumura Y, Mitsui Y, Ogawa Y, Odomari K,
Sakaue S, Namba S, Komuro M, Edamoto M, Watanabe J, Hirota T, Arase N,
Nakamura Y, Nakajima K, Okamoto T, Nishikawa R, Yamamoto K, Suzuki K, Kishikawa
T, Edahiro R, Shirai Y, Naito T, Sasa N, Ishitsuka Y, Furuta J, Kunimoto
K, Kajihara I, Fukushima S, Miyachi H, Matsue H, Kamata M, Momose M, Miyagawa
I, Tanaka H, Ueno M, Bito T, Nagai H, Ikeda T, Horikawa T, Adachi A, Matsubara
T, Nishida E; Biobank Japan Project; Matsuda K, Shojima N, Nakagawa I,
Asano Y, Sato S, Imafuku S, Tada Y, Nishigori C, Jinnin M, Ihn H, Asahina
A, Saeki H, Yamauchi T, Kadowaki T, Kawamura T, Shimada S, Katayama I,
Higasa K, Noguchi E, Sano S, Tanaka Y, Matsuda F, Kumanogoh A, Tamari M,
Satoh T, Fujimoto M, Morita A, Okada Y. Whole-genome sequencing reveals
rare and structural variants contributing to psoriasis and identifies CERCAM
as a risk gene. Cell Genom. 2025 Aug 19:100978. doi: 10.1016/j.xgen.2025.100978.
Epub ahead of print. PMID: 40848718.
72. Kusaka K, Kubo S, Nakayamada S, Miyagawa I, Miyazaki Y, Kanda Y, Todoroki
Y, Ueno M, Kanda R, Setoyama K, Kataoka M, Tanaka Y. Association of exercise-induced
pulmonary hypertension with nailfold capillary density in systemic sclerosis:
a single-center retrospective observational study. Arthritis Res Ther.
2025 Aug 26;27(1):169. doi: 10.1186/s13075-025-03633-5. PMID: 40859364.1.
轟 泰幸
受賞歴
平成２５年 名古屋市立大学 水谷孝文賞
平成２８年 第６０回 日本リウマチ学会 国際ワークショップ賞
平成２９年 第６１回 日本リウマチ学会 国際ワークショップ賞
令和 ２年 第６４回 日本リウマチ学会 国際ワークショップ賞
令和 ３年 第６５回 日本リウマチ学会 国際ワークショップ賞
令和 ４年 第６６回 日本リウマチ学会 国際ワークショップ賞
令和 ７年 第６９回 日本リウマチ学会 国際ワークショップ賞
論文
（文責：久保智史 更新日2023/4/20）
このページの先頭へ
2. Kanda R, Miyazaki Y, Nakayamada S, Fukuyo S, Kubo S, Miyagawa I, Yamaguchi A, Satoh-Kanda Y, Ohkubo N, Todoroki Y, Tanaka H, Ueno M, Nagayasu A, Fujita Y, Aritomi T, Kusaka K, Sakai H, Matsunaga S, Nohara H and Tanaka Y. Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry. Rheumatol Ther. 2025.
3. Kubo S, Miyazaki Y, Nishino T, Fujita Y, Kono M, Kawashima T, Ishigaki
K, Kusaka K, Tanaka H, Ueno M, Satoh-Kanada Y, Inoue Y, Todoroki Y, Miyagawa I, Hanami K, Nakayamada S, Tanaka Y. Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness. Ann Rheum Dis. 2025;84(2):210-20.
4. Miyazaki Y, Nakayamada S, Tanaka H, Hanami K, Fukuyo S, Kubo S, Yamaguchi A, Miyagawa I, Satoh-Kanda Y, Todoroki Y, Inoue Y, Ueno M, Tanaka Y. Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry. RMD Open. 2025;11(1).
5. Ueno M, Iwata S, Yamagata K, Todoroki Y, Sonomoto K, Nagayasu A, Miyagawa I, Kubo S, Miyazaki Y, Miyata H, Kanda R, Aritomi T, Nakayamda S, Tanaka Y. Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus. RMD Open. 2024;10(4).
6. Kusaka K, Miyazaki Y, Nakayamada S, Kubo S, Miyagawa I, Satoh-Kanda Y, Todoroki Y, Ueno M, Tanaka Y. The abundance of regulatory T cell subsets is associated with the clinical outcomes of sarcoidosis. Mod Rheumatol. 2024.
7. Kobayashi H, Miyazaki Y, Nakayamada S, Hanami K,Fukuyo S, Kubo S, Yamaguchi A, Inoue Y, Todoroki Y, Miyata H, Tanaka H, Fujino Y, Hirata S, Tanaka Y. Predictors of the effectiveness to first-line CTLA4-Ig in patients with rheumatoid arthritis: the FIRST registry. Rheumatology (Oxford). 2024.
8. Sakai H, Miyazaki Y, Nakayamada S, Kubo S, Hanami K, Fukuyo S, Yamaguchi A, Miyagawa I, Ueno M, Tanaka H, Todoroki Y, Ohkubo N, Funada M, Matsunaga S, Tanaka Y. Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry. Rheumatology (Oxford). 2024.
9. Ohkubo N, Miyazaki Y, Nakayamada S, Fukuyo S, Inoue Y, Satoh-Kanda Y,Tanaka H, Todoroki Y, Miyata H, Nagayasu A, Funada M, Kobayashi H, Sakai H, Kosaka S, Matsunaga S, Tomoyose Y, Nohara H,Tanaka Y. Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study. Rheumatol Ther. 2024;11(5):1303-19.
10. Miyazaki Y, Nakayamada S, Tanaka H, Hanami K, Fukuyo S, Kubo S, Miyagawa I, Yamaguchi A, Todoroki Y, Inoue Y, Ueno M, Tanaka Y. Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST study. Rheumatology (Oxford). 2024.
11. Sonomoto K, Nakayamada S, Fujino Y, Miyata H, Kubo S, Fujita Y, Inoue Y, Matsunaga S, Iwata S, Hanami K, Todoroki Y, Yoshinari-Korekoda H, Kawabe A, Yamaguchi A, Ueno M, Satoh-Kanda Y, Kanda R, Funada M, Ohkubo N, Kusaka K, Kosaka S, Nagayasu A, Fukuyo S, Nawata M, Miyazaki Y, Tokunaga M, Tanaka K, Okada Y, Tanaka Y. Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study. Rheumatology (Oxford).63(8):2239-48 2024.
12. Miyazaki Y, Funada M, Nakayamada S, Sonomoto K, Tanaka H, Hanami K, Fukuyo S, Kubo S, Yamaguchi A, Miyagawa I, Todoroki Y, Ueno M, Tanaka Y. Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry. Rheumatology (Oxford).63(9):2345-54, 2024.
13. Todoroki Y, Satoh M, Kubo S, Kosaka S, Fukuyo S, Nakatsuka K, Saito K, Tanaka S, Nakayamada S, Tanaka Y. Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in Mixed connective tissue disease. Rheumatology (Oxford). 63(4):1068-75,2024.
14. Kubo S, Miyazaki Y, Todoroki Y, Nagayasu A, Kanda R, Aritomi T, Matsunaga S, Ueno M, Miyagawa I, Sonomoto K, Hanami K, Nakayamada S, Tanaka Y. Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry. Rheumatol Ther 2023;10(6):1705-23.
15. Shan Y, Nakayamada S, Nawata A, Yamagata K, Sonomoto K, Tanaka H, Satoh-Kanda, Y.Nguyen M.P, Todoroki Y, Nagayasu A, Ueno M, Kanda R, Fujita Y, Zhang T, Hao H, Zhou J, Ma X, Anan J, Nguyen A.P, Tanaka Y. TGF-beta3 in differentiation and function of Tph-like cells and its relevance to disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford). 62(7):2463-2474, 2023.
16. Todoroki Y, Kubo S, Nakano K, Miyazaki Y, Ueno M, Satoh Y, Kanda R, Hanami K, Nakatsuka K, Saito K, Nakayamada S and Tanaka Y.
Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology. 61(12):4875-84, 2022.
17. Sumikawa MH, Iwata S, Zhang M, Miyata H, Ueno M, Todoroki Y, Nagayasu A, Kanda R,Sonomoto K, Tomrimoto K, Lee S, Nakayamada S, Yamamoto K, Okada Y and Tanaka Y. An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. Rheumatology. 61(7):3049-59,2022.
18. Zhang M, Iwata S, Sonomoto K, Ueno M, Fujita Y, Anan J, Miyazaki Y, Ohkubo N,
Sumikawa M.H, Todoroki Y, Miyata H, Nagayasu A, Kanda R, Trimova G, Lee S, Nakayamada S, Sakata K and Tanaka Y.mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors. Rheumatology. 61(7):3010-22,2022.
19. Muro Y, Yamano Y, Yoshida K, Oto Y, Nakajima K, Mitsuma T, Kikuchi S, Matsumae A,
Ogawa-Momohara M, Takeichi T, Kondoh Y, Katayama M, Todoroki Y, Tanaka Y, Satoh M. and Akiyama M. Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. J Autoimmun.122:102680,2021.
20. Kubo S, Siebuhr AS, Bay-Jensen AC, Juhl P, Karsdal MA, Satoh Y, Todoroki Y, Nakano Y, Nakayamada S and Tanaka Y. Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. Int J Rheum Dis. 23(4):532-9,2020.
21. Iwata S, Zhang M, Hao H, Trimova G, Hajime M, Miyazaki Y, Ohkubo N, Todoroki Y, Miyata H, Ueno M, Nagayasu A, Nakayamada S, Sakata K and Tanaka Y. Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN-gamma Overproduction in T Helper 1 Cells. Front Immunol.11:593103,2020.
22. Zhang M, Iwata S, Hajime M, Ohkubo N, Todoroki Y, Miyata H, Ueno M, Hao H, Zhang T, Nakayamada S, Yamagata K and Yoshiya Tanaka. Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC homolog 2 by the methyltransferase enhancer of zeste homolog 2. Arthritis Rheumatol.72(7):1143-53,2020.
23. Kubo S, Nakayamada S, Miyazaki Y, Yoshikawa M, Yoshinari H, Satoh Y, Todoroki Y, Nakano K, Satoh M, Smith V, Cutolo M and Tanaka Y. Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. Rheumatology. 58(12):2273-83,2019.
24. Kubo S, Todoroki Y, Nakayamada S, Nakano K, Satoh Y, Nawata A, Saito K, Satoh M, Smith V, Cutolo M and Tanaka Y. Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatology.58(1):120-30,2019.
25. Ishikawa Y, Iwata S, Hanami K, Nawata A, Zhang M, Kaoru Y, Shintaro H, Kei S, Todoroki Y, Nakano K, Nakayamada S, Satoh M and Tanaka Y. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Res Ther. 20(1):240,2018.
26. Ishikawa Y, Miyagawa I, Nakano K, Satoh Y, Todoroki Y, Kubo S, Nawata A, Nakayamada S, Saito K and Tanaka Y. The occurrence of hypertrophic pachymeningitis with infiltration of IgG4-positive plasma cells and with different aetiology: report of three cases. Modern Rheumatology Case Reports. 1(2):108-112,2017.